- Home
- NKSH vs NERV Comparison
NKSH vs NERV Comparison
Compare NKSH & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NKSH | NERV |
|---|---|---|
| Founded | 1891 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 243.3M | 207.7M |
| IPO Year | 1995 | 2014 |
Fundamental Metrics
Financial Performance| Metric | NKSH | NERV |
|---|---|---|
| Price | $38.41 | $6.31 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 12.4K | ★ 98.5K |
| Earning Date | 04-23-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.96% | N/A |
| EPS Growth | N/A | ★ 104.12 |
| EPS | ★ 1.56 | N/A |
| Revenue | $7,474,000.00 | ★ $41,175,600.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $24.62 | ★ N/A |
| Revenue Growth | ★ 5.68 | N/A |
| 52 Week Low | $23.75 | $1.15 |
| 52 Week High | $40.00 | $12.46 |
Technical Indicators
Market Signals| Indicator | NKSH | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 68.65 | 69.16 |
| Support Level | $37.54 | $5.66 |
| Resistance Level | $38.72 | $6.69 |
| Average True Range (ATR) | 0.83 | 0.57 |
| MACD | -0.13 | 0.11 |
| Stochastic Oscillator | 53.67 | 84.44 |
Price Performance
Historical ComparisonAbout NKSH National Bankshares Inc.
National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural, commercial real estate, construction for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary, National Bankshares Financial Services, Inc. The company earns its revenues from interest and fees on loans, non-interest income, and investments.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.